(+) Endo announces FDA approval of a new formulation of Opana ER designed to be crush-resistant (Endo Pharmaceuticals) - Dec 12, 2011 - FDA approved new formulation of Opana ER; Endo is committed to executing a seamless transition in 2012 from original formulation to new formulation, which utilizes the proprietary INTAC technology owned by Grunenthal; Endo also announced that U.S.P.T.O issued patent number 8,075,872 on Dec 13, 2011; The patent covers new formulation of Opana ER and is expected to provide protection until Nov 2023
FDA approval • Patent update • Product update • Pain
|
|
CHADDS FORD, Pa., Dec. 12, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Opana® ER designed to be crush-resistant.
"FDA's approval of this new formulation of Opana ER is an important milestone for both the Long Acting Opioid category as well as Endo's branded pharmaceutical portfolio," said Dr. Ivan Gergel, M.D., executive vice president, R&D and chief scientific officer, Endo Pharmaceuticals. "Patient safety is our top concern and addressing appropriate use of opioids is a responsibility that we take very seriously. We firmly believe this new formulation of Opana ER, coupled with our long-term commitment to awareness and education around appropriate use of opioids will benefit patients, physicians and payers.
Endo is committed to executing a seamless transition in 2012 from the original formulation to the new formulation, which utilizes the proprietary INTAC™ technology owned by Grunenthal, a partner in the development of the product. The new formulation will continue to be called Opana ER with the same dosage strengths, color and packaging and similar tablet size and shape. Also, the FDA approval signifies that there is no significant difference in the rate and extent of absorption of the therapeutic ingredient between this new formulation and the original formulation of Opana ER.
Endo also announced that the U.S. Patent and Trademark Office will issue patent number 8,075,872 on Dec. 13, 2011. The patent covers the new formulation of Opana® ER and is expected to provide protection until November 2023. This new patent will be listed in the FDA's Orange Book with respect to the new formulation of Opana ER.
Because Opana ER contains oxymorphone, a CII controlled substance, it remains a Schedule II opioid with all the attendant risks, specifically that the drug has a high potential for abuse. Use, misuse, or abuse of the drug may lead to physical dependence or addiction (addiction is sometimes referred to as "psychological dependence"). In addition, alteration of the tablet in any manner poses significant risks of overdose and death. It has not been established that this new formulation of Opana ER is less subject to misuse, abuse, diversion, overdose, or addiction. The Full Prescribing Information contains warnings about the potential for abuse, diversion, overdose and addiction, including a boxed warning (see below).
|